KURA Stock Recent News
KURA LATEST HEADLINES
September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies
Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian T. Powl - Chief Commercial Officer Greg Mann - Corporate Participant Mollie Leoni - Chief Medical Officer Thomas Doyle - Senior Vice President of Finance & Accounting Troy Edward Wilson - Chairman, CEO & President Conference Call Participants Ellen Horste - TD Cowen, Research Division Eric Tatenda Musonza - UBS Investment Bank, Research Division Jason Eron Zemansky - BofA Securities, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Peter Green - Unidentified Company Peter Richard Lawson - Barclays Bank PLC, Research Division Roger Song - Jefferies LLC, Research Division Suranjit Mukherjee - BTIG, LLC, Research Division Wei Ji Chang - Leerink Partners LLC, Research Division Operator Hello, and welcome, everyone, joining today's Second Quarter 2025 Kura Oncology, Inc. Financial Results Conference Call.
Kura Oncology (KURA) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of $0.15. This compares to a loss of $0.59 per share a year ago.
– FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with regulatory review timeline – – KOMET-017-IC (intensive chemotherapy) and NIC (non-intensive chemotherapy) phase 3 studies in newly diagnosed AML on track to start in 2H 2025 – – Three clinical abstracts from Kura's farnesyl transferase inhibitors (FTI) development program accepted for presentation at the 2025 ESMO Congress – – $630.7 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company co
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 646,700 shares of common stock to thirty-five (35) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 141,750 shares of common stock to eight (8) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology is a Strong Buy due to ziftomenib's positive Phase 2 data in newly diagnosed AML mutant patients and upcoming FDA Priority Review for relapsed/refractory NPM1-m/KMT2A-r AML. The pipeline is expanding beyond monotherapy, with promising results in combination regimens for newly diagnosed AML patients. Strong financials, including $703M in cash and a supportive partnership with Kyowa Kirin, minimize dilution risk and support operations through commercialization for 1st-line setting.
Investors need to pay close attention to KURA stock based on the movements in the options market lately.
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML –